Larazotide, with the CAS number 258818-34-7, is a synthetic peptide that has garnered attention for its potential therapeutic applications, particularly in the treatment of celiac disease. It functions primarily as a tight junction modulator, aiming to enhance intestinal barrier function by influencing the permeability of the intestinal epithelium. Larazotide is designed to prevent the passage of harmful substances across the gut lining, thereby reducing the inflammatory response associated with gluten exposure in susceptible individuals. The compound is typically administered orally and has been evaluated in clinical trials for its efficacy and safety profile. Its mechanism of action involves the modulation of the zonulin pathway, which plays a crucial role in regulating tight junction integrity. Larazotide is characterized by its peptide structure, which contributes to its specificity and biological activity. As research continues, larazotide may offer a novel approach to managing celiac disease and improving the quality of life for affected individuals.

Larazotide

258818-34-7: Larazotide, with the CAS number 258818-34-7, is a synthetic peptide that has garnered attention for its potential therapeutic applications, particularly in the treatment of celiac disease. It functions primarily as a tight junction modulator, aiming to enhance intestinal barrier function by influencing the permeability of the intestinal epithelium. Larazotide is designed to prevent the passage of harmful substances across the gut lining, thereby reducing the inflammatory response associated with gluten exposure in susceptible individuals. The compound is typically administered orally and has been evaluated in clinical trials for its efficacy and safety profile. Its mechanism of action involves the modulation of the zonulin pathway, which plays a crucial role in regulating tight junction integrity. Larazotide is characterized by its peptide structure, which contributes to its specificity and biological activity. As research continues, larazotide may offer a novel approach to managing celiac disease and improving the quality of life for affected individuals.

Larazotide: octapeptide from V. cholerae, treats Coeliac disease by inhibiting paracellular permeability.

<p>Custom research peptide; min purity 95%. For different specs please use the Peptide Quote Tool</p>

CAS 258818-34-7

Larazotide

Larazotide

Ref: TM-T15711L

Larazotide

Ref: 3D-PP50704